Next Phase Newsletter

A boutique venture capital firm manages an evergreen USD fund. The fund focuses on healthcare industry, generally participating in Series A or B rounds but would also consider seed and growth-stage funding. Typical equity investment size ranges from $3-5M. The firm is open to both leading and co-investing. The firm is actively seeking new opportunities from across the world with a focus on companies in China, U.S., Europe, and Israel. The firm helps portfolio companies get into massive and fast-growing markets of China and Asia, and assists Chinese companies to expand abroad. 
 
The firm is most interested in biopharma, biotechnology, medical devices, artificial intelligence. Within medtech, the firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy. 
 
The firm is in search of ambitious companies with strong, experienced management teams. The firm takes a hands-on approach to portfolio companies and can work with incomplete teams. The firm can contribute expertise in essential services: branding, marketing, channel development, overseas expansion, human resources and finance. 
 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in the US is dedicated to advancing healthier outcomes for all by partnering with technology-powered innovators. The team consists of industry-seasoned leaders with deep health-tech experience. The firm will invest in Seed – Series B rounds, with a sweet spot for Series A. The firm makes initial equity investments of $3M-$10M and typically leads rounds. The firm will invest globally. 
 
The firm invests in healthcare software, services, and solutions based digital health companies. 
 
The firm has no strict team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A private investment vehicle established recently and headquartered in Asia is mainly interested in investing in global healthcare companies, co-investing in Pre-Seed up to Series A rounds. Currently, they have five portfolio companies spanning biotech, digital health, and medical devices. Initial check size is flexible, but the firm will allocate up to USD $400k up to Seed rounds and USD $1-2M up to Series A. 
 
The firm is open to biotech, first-in-class drugs, medical devices, digital health, and diagnostics. Though indication and technology-agnostic, next generation and innovative technologies are of interest. 
 
The firm does not have strict company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A public company based in China has its core businesses in-vitro diagnostics and radiation therapy. The corporate fund of this company is looking to work with early-stage medical device companies using a variety of structures, including equity investments and M&A. The firm is looking to engage in Seed to Series B/C and the average check size is usually less than 10M USD. The firm is open to opportunities worldwide and prefers companies with some sort of China angles. The firm is looking to make 3-4 new investments within the next 12 months. 
 
While the firm’s core business is in IVD and radiation therapy, the firm is interested in medical devices of all classes. 
 
The firm does not have any specific requirements for the company’s management team, but they do prefer companies with a China angle. The firm is open to both leading and co-investing and is likely to take a board seat when leading. The firm looks to be an active investor and strategically collaborate with their portfolio companies to create synergies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A joint venture founded between a family office and a holding company is interested in Series A and B medical device companies in the U.S. and Western Europe that are near FDA approval. The firm is also open to Korean and Japanese companies. Typical check sizes range between USD $500k-1.5M, preferring to lead transactions. The firm will also co-invest with the family office’s other investment vehicles to secure right in late-stage revenue-generating companies with a clear path to exit within an 18-24 month time frame. 
 
The firm is interested open to all classes of medical devices, but mainly focuses on human implants. Their core focus is in the neuromuscular space, including orthopedics and spine implants. They are also interested in cardiology, vascular devices, surgical devices, oncology biopharma. Currently, they are looking to expand their core area and look at more cardiovascular, arterial and peripheral devices. Companies should be near FDA approval with proven technology. 
 
The firm requires to take a board seat, observer at minimum. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm headquartered in Western Europe is led by a small, academically focused team located throughout the globe in London, the USA, and Israel. The firm makes, on average, 4-6 investments per year with a total of 20 initial ticket investments via their current fund. The firm invests in pre-clinical companies in early stages, with a sweet spot for Seed and Series A rounds. The firm is open to making investments via any investment vehicle, typically in the form of equity, safe or convertible notes. The firm will invest up to $5-6M. The firm invests globally, with a large number of investments in North America. 
 
The firm invests solely in therapeutics. The firm is focused on “advanced therapeutics”, encompassing anything that is highly targeted such as gene therapy, cell therapy, siRNA, genetic medicine and computational biology. The firm is indication agnostic, with a large interest, however, in oncology. 
 
The firm will co-lead or syndicate rounds, with a preference to co-lead. The firm has no specific team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm actively invests in pre-seed and seed stage companies. Typical initial size of investment ranges from $1-1.5M. The firm focuses on the following areas: digital economy, climate & environment, health & well-being. The firm is strongly interested in companies based in North America and Latin America. 
 
Historically, the firm has been agnostic towards technology area and indications. That said, the firm is currently interested in exploring opportunities in new modalities and biologics, and expanding their interests in peptide-based therapies and induced proximity therapeutics (i.e. molecular glues, PROTACs). The firm invests mainly in pre-clinical and early clinical therapeutics. The firm actively invests in therapeutics, diagnostics, and life science tools. 
 
The firm seeks to work with exceptional entrepreneurs who are passionate about their work, and is open to working with first-time entrepreneurs. The firm’s investment process starts from an initial meeting and evaluating the opportunity, a decision analysis including the addressed market, life stages assessment, and a final assessment, and if choosing to move forward, proceeding with legal due diligence and signing/execution. To date, the firm has led about 50% of their deals, and following in the other half. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.